Yuliya Pylayeva

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. ncbi Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling
    Yuliya Pylayeva
    Cell Biology Program, Memorial Sloan Kettering Cancer Center MSKCC, New York, New York, USA
    J Clin Invest 119:252-66. 2009
  2. ncbi Analysis of integrin signaling in genetically engineered mouse models of mammary tumor progression
    Yuliya Pylayeva
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, and Sloan Kettering Division, Weill Graduate School of Medical Sciences, Cornell University, New York, New York, USA
    Methods Enzymol 426:439-61. 2007
  3. ncbi Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis
    Wenjun Guo
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021 USA
    Cell 126:489-502. 2006

Collaborators

Detail Information

Publications3

  1. ncbi Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling
    Yuliya Pylayeva
    Cell Biology Program, Memorial Sloan Kettering Cancer Center MSKCC, New York, New York, USA
    J Clin Invest 119:252-66. 2009
    ....
  2. ncbi Analysis of integrin signaling in genetically engineered mouse models of mammary tumor progression
    Yuliya Pylayeva
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, and Sloan Kettering Division, Weill Graduate School of Medical Sciences, Cornell University, New York, New York, USA
    Methods Enzymol 426:439-61. 2007
    ..In this chapter, we describe a collection of cell biological and genetic methods that may aid in characterizing the roles of integrin signals in mammary tumorigenesis...
  3. ncbi Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis
    Wenjun Guo
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021 USA
    Cell 126:489-502. 2006
    ..These results indicate that beta 4 integrin promotes tumor progression by amplifying ErbB2 signaling and identify beta 4 as a potential target for molecular therapy of breast cancer...